

## S-1 Guideline dermal and subcutaneous leiomyosarcoma (LMS)

LMS/operable

### Surgical treatment/safety margin (SM)

Dermal LMS: Primarily microscopically controlled R0, extension of the SM to 1 cm

Subcutaneous LMS: Primarily microscopically controlled R0, if possible extension of the SM to 2 cm, or rather to the fascia (or according to an interdisciplinary tumor conference)

### Diagnostics (imaging)

None in standard cases.

In case of suspicion or evidence of locoregional metastasis: ultrasound of regional lymph nodes

In the case of non-displaceable tumours/ suspected deep infiltration: locoregional CT or MRI

### Adjuvant radiation therapy

LMS R0 and small tumours: none

LMS R1 or R-2 resection, small safety margin or large tumours

(LMS > 5cm): recommended

LMS/non-resectable or metastatic

### Radiotherapy:

In palliative, inoperable situations: therapeutic radiotherapy

### Medical treatment:

Individual therapy decision

E.g. doxorubicin or anthracycline-based combination therapy (in case of rapid progression)

Follow-up care:

	Cutaneous/dermal LMS		Subcutaneous LMS		Relapse LMS		LMS with locoregional, lymph node or distant metastases
Year	1-2	3-5	1-2	3-5	1-2	3-5	1-5
Clinical follow-up (months)	6	12	3	6	3	6	Individual management
Ultrasound of scar and surroundings	-	-	6	6	6	6	Individual management
Sectional imaging (CT chest/abdomen)	-	-	Individual management				Individual management

Further information:

Reference: Helbig et al. S1-guideline cutaneous and subcutaneous leiomyosarcoma  
<https://doi.org/10.1111/ddg.14989>